Evotec receives milestone payment for start of Phase II trial in its multi-target alliance with Bayer

Hamburg, Germany, 19 Jul 2018

Evotec AG announced today that its multi-target alliance with Bayer in the field of endometriosis has advanced a promising small molecule into Phase II clinical development for the treatment of chronic cough, resulting in a payment of € 4 m to Evotec.